Evidence map›Paper›PMID 29146891›Full record

ArticleAnnals of transplantation2017

Heart Transplantation and Risk of Cardiac Vasculopathy Development: What Factors Are Important?

Małgorzata Sobieszczańska-Małek, Jerzy Korewicki, Krzysztof Komuda, Małgorzata Karczmarz, Sylwia Szymańska, Alicja Cicha-Mikołajczyk, Paweł Bekta, Adam Parulski, Maciej Pronicki, Wiesława Grajkowska and 5 more

Abstract read
In one paragraph

Article in Annals of transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Małgorzata Sobieszczańska-MałekDepartment of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.
Jerzy KorewickiDepartment of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.
Krzysztof KomudaDepartment of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.
Małgorzata KarczmarzDepartment of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.
Sylwia SzymańskaDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Alicja Cicha-MikołajczykDepartment of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, Institute of Cardiology, Warsaw, Poland.
Paweł BektaDepartment of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland.
Adam ParulskiDepartment of Cardiosurgery and Transplantology, Institute of Cardiology, Warsaw, Poland.
Maciej PronickiDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Wiesława GrajkowskaDepartament of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Grzegorz MałekDepartment of Radiology, National Institute of Geriatrics, Reumathology and Rehabilitation, Warsaw, Poland.
Przemysław LeszekDepartament of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.
Maria KaczorowskaStudent of First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Mariusz KuśmierczykDepartment of Cardiosurgery and Transplantology, Institute of Cardiology, Warsaw, Poland.
Tomasz ZielińskiDepartament of Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to find the main risk factors for development of cardiac allograft vasculopathy (CAV), especially factors identified before the surgical procedure and factors related to the recipient profile and the medical history of the donor. MATERIAL AND METHODS There were 147 patients who had heart transplantation (HT) included in this study: mean age was 45.8±15.3 years. All study patients had coronary angiography after HT. Analyzed risk factors were: non-immunologic recipient risk factors (age of transplantation, smoking, hypertension, lipids, diabetes, obesity and weight gain after HT), immunologic recipient risk factors (acute cellular rejection (ACR), acute humoral rejection (AMR), cytomegalovirus (CMV) episodes), and donor-related risk factors (age, sex, catecholamine usage, ischemic time, compatibility of sex and blood groups, cause of death, cardiac arrest). RESULTS CAV was recognized in 48 patients (CAV group); mean age 53.6±13.6 years. There were 99 patients without CAV (nonCAV group); mean age 48.3±15.5 years. A univariate Cox analysis of the development of coronary disease showed statistical significance (p<0.05) for baseline high-density lipid (HDL), ACR, AMR, CMV, and donor age. Multivariate Cox regression model confirmed that only baseline HDL, episodes of ACR, donor age, and CMV infection are significant for the frequency of CAV after HT. CONCLUSIONS Older donor age is highly associated with CAV development. Older donor age and low level of HDL in heart recipients with the strongest influence of immunologic risk factors (ACR, CMV infection) were linked with development of CAV.

Indexed as

AdultAge FactorsCoronary AngiographyFemaleGraft RejectionHeart DiseasesHeart TransplantationHumansImmunosuppressive AgentsMaleMiddle AgedRisk FactorsImmunosuppressive Agents

Identifiers

PMID29146891
PMCPMC6248309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.